Markets:

Overview

News

Currencies

International

Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

15.06 -0.18 (-1.18%)

Streaming Delayed Price Updated: 11:21 AM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824

September 14, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization ↗

September 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...

Via Benzinga

KalVista Pharmaceuticals Reports First Fiscal Quarter Results

September 09, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

August 23, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 09, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

July 13, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 12, 2021

Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life...

Via Benzinga

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

July 12, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix ↗

July 11, 2021

Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, Inc. (NASDAQ: PRVB) faced a setback...

Via Benzinga

18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗

July 10, 2021

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the...

Via Talk Markets

18 Key Biopharma Catalysts To Keep An Eye On In Q3 ↗

July 10, 2021

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne...

Via Benzinga

KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)

June 28, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

June 05, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

May 27, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Kalvista Pharmaceuticals Stock Shows Rising Relative Strength ↗

May 19, 2021

A Relative Strength Rating upgrade for Kalvista Pharmaceuticals shows improving technical performance.

Via Investor's Business Daily

The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗

May 31, 2021

After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...

Via Benzinga

KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12th C1-Inhibitor Deficiency & Angioedema Workshop

May 10, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical Officer

May 03, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

31 Stocks Moving In Tuesday's Mid-Day Session ↗

April 20, 2021

Gainers MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) gained 20.8% to $5.32 after dropping more than 10% on Monday. Takung Art Co., Ltd. (NASDAQ: TKAT) shares surged 18.2% to $21.08...

Via Benzinga

Why Crispr, KalVista And Syndax Are Moving Today ↗

April 20, 2021

CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma...

Via Benzinga

KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824 ↗

April 20, 2021

Two months after KalVista Pharmaceuticals Inc (NASDAQ: KALV) reported positive Phase 2 results for its lead drug KVD900, an oral therapy meant to stem the...

Via Benzinga

The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex ↗

April 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...

Via Benzinga

KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824

April 20, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.